Skip to content
Biodatica
Start free

Hoffmann-La Roche

La Jolla, California

OncologyPhase IIIListed · RHHBY

This company trades under its own ticker, so it sits outside Biodatica’s pre-ticker window. The record stays here because its filings are real, but the feed leaves listed companies out unless you ask for them.

Compare Sign in to watch

What changed

Phase III trial registered: A Study to Evaluate Safety and Efficacy of Ocrelizumab in Comparison With Fingolimod in Children and Adolescents With Relapsing-remitting Multiple Sclerosis (RRMS)

5d agoTrial registeredJul 15, 2026Source filing (opens the source filing in a new tab)

Momentum

87no change

Momentum 87 out of 100, unchanged since the last recompute.

Accelerating: several high-weight events landed recently.

Runway (estimate)

—unknown

No disclosed raise on file, so there is nothing to model from.

Stage

Phase III

The furthest-along thing in the public record. Not a projection.

Runway is an estimate: the last disclosed raise (SEC Form D) minus a modeled burn rate for the company’s stage and therapeutic area. It is not a disclosure, and companies routinely raise non-dilutive money we can’t see. How this is calculated.

Grant to raise

Every record Biodatica has resolved onto this company, newest first, each linked to the filing it came from. Where a source publishes no stable deep link for a record, the identifier is shown so you can look it up yourself.

  1. Trial

    PHASE1/PHASE2 registered

    Apr 12, 2023

    Squamous Cell Carcinoma of the Head and Neck · COMPLETED · sponsor: Hoffmann-La Roche · A Study Evaluating Efficacy and Safety of Multiple Treatment Combinations in Patients With Locally Advanced Squamous Cell Carcinoma of the Head and Neck (Morpheus-Head and Neck Cancer)

    ClinicalTrials.gov · NCT05459129 (opens the source filing in a new tab)

  2. Trial

    PHASE3 registered

    May 19, 2022

    Relapsing-remitting Multiple Sclerosis · ACTIVE_NOT_RECRUITING · sponsor: Hoffmann-La Roche · A Study to Evaluate Safety and Efficacy of Ocrelizumab in Comparison With Fingolimod in Children and Adolescents With Relapsing-remitting Multiple Sclerosis (RRMS)

    ClinicalTrials.gov · NCT05123703 (opens the source filing in a new tab)

  3. Trial

    PHASE2 registered

    Mar 2, 2021

    Squamous Cell Carcinoma of Head and Neck · COMPLETED · sponsor: Hoffmann-La Roche · A Study of Atezolizumab Plus Tiragolumab and Atezolizumab Plus Placebo as First-Line Treatment in Participants With Recurrent/Metastatic PD-L1 Positive Squamous Cell Carcinoma of the Head and Neck

    ClinicalTrials.gov · NCT04665843 (opens the source filing in a new tab)

  4. Trial

    PHASE1/PHASE2 registered

    May 3, 2016

    Solid Tumors, CNS Tumors · ACTIVE_NOT_RECRUITING · sponsor: Hoffmann-La Roche · Study Of Entrectinib (Rxdx-101) in Children and Adolescents With Locally Advanced Or Metastatic Solid Or Primary CNS Tumors And/Or Who Have No Satisfactory Treatment Options

    ClinicalTrials.gov · NCT02650401 (opens the source filing in a new tab)

Biodatica publishes impersonal research shown identically to every subscriber. This dossier is informational only, it is not investment advice, and the momentum and runway figures are estimates derived from public filings. The underlying records are U.S. government works. Disclosures · Data sources